Elliot Marseille, Dan Grossman, Sherry Rais, Leslie Nylund
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.
Henry Elkus
Dr. Smith and Dr. Jones analyze the economic impact of drug pricing and care costs on the psychedelic market at PS2023.
Integration of psychedelic therapy into healthcare requires clinics to provide safe care. Planning infrastructure carefully, considering environmental factors, is crucial for successful delivery of psychedelic services.
Daniel Kelly, Gregory Kearns, Payton Nyquvest
Traditional cultures use psychedelics, but companies are patenting therapies and compounds based on them. Discussion explores IP system improvements for innovation and public health protection.
Chris Byrnes, Laurel Kilgour, Leslie Booher
Substance use disorder cases doubled during the pandemic, with over 100,000 drug overdose deaths in 2020. Research explores psychedelic-assisted therapy as a potential paradigm shift in addiction treatment efficacy.
Michael Bogenschutz, Matthew Johnson, Deborah Mash, Peter S. Hendricks
Panel explores how telemedicine can enhance psychedelic therapy practice, discussing benefits and risks of virtual care in light of pandemic-induced regulatory changes and improved meeting tech.
Juan Pablo Cappello, Jonathan Sabbagh
Imran Khan presents findings of the Psychedelic Insight Poll, a national survey by the Berkeley Center for the Science of Psychedelics to understand public perceptions of psychedelic substances. The poll
Imran Khan
Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.
Paul Summergrad, Tom Insel, Rachel Nuwer
NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study
Joshua A Gordon
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.